Lee et al. confirmed that undetectable ctDNA at baseline is an independent predictor of prolonged survival in melanoma patients treated with anti-PD-1 with better performance compared to other parameters such as LDH, disease burden, and Eastern Cooperative Oncology Group (ECOG) performance status [29]. This evidence concerns the gene PDCD1 and melanoma.